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Introduction
Chronic myeloid leukemia (CML) is one of a group 
of diseases referred to as a myeloproliferative disorder 
of pluripotential hemopoietic stem cells (HSCs). Here, 
chromosomal translocation leads to an oncogenic 
BCR–ABL gene fusion, which enhances tyrosine kinase 
(TK) activity. Anomalously activated kinases disturb 
downstream signaling pathways and cause abnormal 
proliferation, differentiation and resistance to cell death 
(Flis and Chojnacki, 2019). Cancer susceptibility and 
CML is related to inherited differences in the capability of 
xenobiotic enzymes to eliminate foreign agents (Kassogue 
et al., 2015). xenobiotic metabolizing enzymes are a 
primary line of defense against bioactive invaders present 
in tissues and organs (Rekka et al., 2019).
Xenobiotic metabolizing enzymes are classified into 
Phase I enzymes: (Cytochrome p450), Phase II enzymes 
(Glutathione-s-transferases, N-acetyltransferases), 
and Phase III  systems, comprising multidrug 
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resistance-associated proteins (MRPs) (Wu and Lin, 2019; 
Arana et al., 2016). Acetylation is a critical processes of 
xenobiotic metabolism and involves catalysis by acetyl 
CoA-dependent aryl amine N-acetyltransferase (NAT) 
enzymes. This plays an essential role in protein synthesis, 
drugs biotransformation and DNA regulation (Santos et 
al., 2016). 
NAT2 is located on chromosome 8 (8p21.3-23.1 and 
8p22) (Hernández-González et al., 2018) and is a Phase II 
drug-metabolizing enzyme. It catalyzes the detoxification 
of common carcinogens and the acetylation of numerous 
clinically used drugs eg: isoniazid, sulfonamides, 
procainamide, and hydrazine (Adithan and Subathra, 
2016). 
The NAT2 gene is highly polymorphic with more 
than a hundred described variant alleles (Aklillu et al., 
2018), and alterations in its structure lead to a variety of 
responses such as susceptibility of cancer and adverse 
drug reactions (Dursun et al., 2018). Its polymorphisms 
are classified as rapid, intermediate, and slow acetylation 
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phenotypes, dependent on the degree of alteration of 
gene and protein products (Salazar-González et al., 2018; 
Selinski et al., 2015). 
Several studies have attempted to explain the 
association between NAT2 polymorphism and numerous 
cancer types including breast, lung cancer, acute 
lymphoblastic leukemia and acute myeloid leukemia (Liu 
et al., 2015; Zou et al., 2017; Hara et al., 2017). However, 
there are only a limited number of published studies on 
its association with CML (Ouerhani et al., 2011; Lemos 
et al., 1999), and this study focuses on the impact of 
NAT2 (C481T (rs1799929), G590A (rs1799930), A803G 
(rs1208) and G857A (rs1799931) polymorphisms on the 
disease (Santos et al., 2016).
Materials and Methods
The study comprised 200 patients with CML 
(Philadelphia chromosome positive), and 100 healthy 
control subjects. Transcript analysis was performed in 
the cytogenetic lab in the Radiation and Isotopes Center 
of Khartoum (RICK), between August 2014 and August 
2017. Subject consent was obtained from donors and the 
protocol ratified by the research committee of the Faculty 
of Medical Laboratory Science at Al-Neelain University.
CML diagnosis was based on hematological features, 
cytogenetics and the detection of BCR-ABL. 
Genotyping analysis
A sample of EDTA anticoagulated blood (3ml) 
was collected from each subject for hematological and 
molecular analysis. A blood cell count was first performed 
with an automated cell counter (Sysmex KX-21N) and the 
DNA then extracted by the guanidine chloride procedure. 
Genotyping of NAT2 was achieved by polymerase chain 
reaction and restriction fragment length polymorphism 
(PCR-RFLP) (Michael et al., 2018).
PCR amplification was undertaken with published 
primers (Oqal et al., 2012), and the polymorphic reaction 
performed using a Protothermal Biometra T Advanced 
Cycler - under the protocol designated by computer 
program; Optimase Protocol Writer™(touch down PCR. 
RFLP analysis was performed to manufacturer’ 
instructions using endonuclease KpnI, DdeI, TaqI, and 
BamHI for the detection of mutations C481T, C590A, 
A803G and G857A, (NEW ENGLAND Bio Labs), 
respectively (Ben et al., 2017).
Post PCR, the fragment length for all NAT2 
polymorphisms were 547bp and previously reported 
restricted enzymes under PCR-RFLP analysis is listed 
in Table 1.
Statistical analysis
The Normality test was used for quantitative data 
with non-parametric data analyzed using ANOVA and 
Kruskal Wallis. A Chi square test was also used within 
and between groups and logistic regression was utilized 
to calculate Odds ratios (ORs). 95% confidence intervals 
(CI) were calculated using SPSS 25.0 software (SPSS Inc, 
Chicago, IL, USA), and a p-value benchmark of < 0.05 
was considered statistically significant.
Results
The frequency of NAT2 polymorphisms according 
to gender among the patients was displayed in Table 2. 
A total of 200 CML patients were enrolled in this study. 
CML patients comprised of 132 males and 68 females. 
Regrading to NAT2 gene C481T polymorphism in the 
case group, the frequencies of the males were carrying 
CC, CT, and TT genotypes were 1.5%, 12.5%, and 52%, 
with a frequency of 0.5%, 6%, and 27.5 in the females. 
Whereas the frequencies of genotypes AA, AG, and GG 
in NAT2 gene A803G polymorphism in the male were 
36.5%, 9%, and 20.5%, and 19%, 6.5% and 8.5% in 
females, respectively. The GG, GA, and AA genotypes 
of NAT2 G590A polymorphism were 14%, 38.5%, and 
13.5% among the males, and 5.5%, 20.5%, and 8% in the 
females. Finally, the males carrying the GG, GA, and AA 
genotypes of NAT2 gene G857A SNP were 23.5%, 0.5%, 
and 42%, whereas, in the females, 15.5%, 0.5%, and 18% 
respectively. None of the differences between genders 
were statistically significant at (P>0.05). Therefore, 
CML patients showed no statistical difference in NAT2 
genotyping according to gender.
The distribution by age with NAT2 genotypes among 
case groups with CML, is shown in Table 3. The overall 
mean age of CML patients was 45.06 ±12.337yrs. The 
mean age of individuals carrying CC, CT, TT genotypes 
of NAT2 C481T gene polymorphism were 49.5 ±5.6, 45.41 
±11.8, and 44.86 ±12.7yrs, respectively. The mean age 
of CML patients carrying AA, AG, and GG of NAT2*5G 
(A803G) gene polymorphism were 46.12 ±11.8, 43.06 
±10.5, and 44.09 ±14.2yrs, respectively. In the case of 
NAT2 (G590A) gene polymorphism, the mean age of 
the individuals carrying the GG, GA, and AA genotypes 
Polymorphism Enzyme -unite  Wild type Mutant type 
481C>T Kpn 1(2U) CC: 433 and 114 bp Heterozygous CT: 547,433 and 114bp
Homozygous TT: 547bp
857G>A GG:490+57 bp Heterozygous GA: 547,490 and 57bp
Homozygous AA: 547bp
590G>A BamH 1(4U)) GG:222,170 and155bp Heterozygous GA:392,222,170 and 155 bp 
Homozygous AA:392 and 155 bp
803A>G Taq1(4U)  AA: 345 ,137and 65 bP Heterozygous AG: 345,137,114 and 65bp
Homozygous GG:345,114and 65 bp
Table 1. Restriction Fragment Pattern of Various NAT2 Polymorphisms Enzyme Units BP Fragments 
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was slightly higher among CML patients (18.5%) than 
the control (15.0%), but not of statistical significance 
(p = 0.677). 
A similar statistical difference was found in frequency 
of the 481 TT genotype, which was only slightly higher in 
the control (84.0%) than the patient group (79.5%), (OR 
= 0.473, 95% CI:0.052-4.302, p = 0. 506). Moreover, 
little difference in T allele frequency was found, it being 
recorded in 92.5% of the control and 88.75% of CML 
patients, with a p =0.149. 
From NAT2 A803G samples however, frequency of 
803AA was significantly higher among CML patients 
compared to the control, its presence being 55.5% and 
were 44.79 ±12.7, 45.23 ±12.3, and 44.81 ±12.4yrs 
respectively. Whereas, the mean ages of individuals 
carrying GG, GA, and AA genotypes were 45.69 ±11.1, 
50.00 ±11.3, and 44.56 ±13.2yrs respectively. The data 
showed that no significant differences were observed 
with age regarding the presence of NAT2 C481T, A803G, 
G90A ,and G857A genotypes.
The distribution of NAT2 C481T, A803G, G590A and 
G857A genotypes and alleles in CML patients and the 
control was also taken, with the following results:
Frequency of the NAT2481 CC genotype was slightly 
higher among CML patients (2.0%) when compared to the 
control (1.0%). Additionally, 481CT genotype frequency 
Genotyping Male Female P-value
NAT2*5A 
(C481T)
CC 3 (1.5%) 1(0.5%) 0.9
CT 25 (12.5%) 12 (6%)
TT 104 (52%) 55 (27.5%)
NAT2*5G 
(A803G)
AA 73 (36.5%) 38 (19%) 0.487
AG 18 (9%) 13 (6.5%
GG 41 (20.5%) 17 (8.5%)
NAT2*6B 
(G590A)
GG 28 (14%) 11 (5.5%) 0.667
GA 77 (38.5%) 41 (20.5%)
AA 27 (13.5%) 16 (8%)
NAT2*7B 
(G857A)
GG 47 (23.5%) 31 (15.5%) 0.328
GA 1 (0.5) 1 (0.5)
AA 84 (42%) 36 (18%)
Total 132 (66%) 68 (34%)
Table 2. Frequency of NAT2 Genotyping According to 
Gender among Patient 
Genotype (N) Mean  ±SD P- value 
NAT2*5A 
(C481T)
CC (4) 49.5  ±5.6 0.608
CT (37) 45.41 ±11.8
TT (159) 44.86 ±12.7
NAT2*5G 
(A803G)
AA (111) 46.12 ±11.8 2.15
AG (31) 43.06 ±10.5
GG (58) 44.09  ±14.2
NAT2*6B 
(G590A)
GG (39) 44.79 +12.7 0.83
GA (118) 45.23 ±12.3
AA (43) 44.81 ±12.4
NAT2*7B 
(G857A)
GG (78) 45.69 ±11.1 0.658
GA (2) 50.00+11.3
AA (120) 44.56+ 13.2
Mean age 45.06 ±12.337
Table 3. Age Distribution According to NAT2 Genotypes 
among Case Group with CML 
Polymorphisms Patient N = 200 (%) Control N= 100 (%) Odd ratio 95% CI P-value
NAT2C481T CC 4 (2.0) 1 (1.0) Ref
CT 37 (18.5) 15 (15) 0.617 0.064-5.981 0.677
TT 159 (79.5) 84 (84) 0.473 0.052-4.302 0.506
C allele 45 (11.3) 15 (7.5) 0.639 0.85-2.88 0.149
T allele 355 (88.8) 185 (92.5)
NAT2A803G AA 111 (55.5) 10 (10.0) Ref
AG 31 (15.5) 64 (64.0) 0.044 0.020-.095 0.000*
GG 58 (29.0) 26 (26.0) 0.201 0.091-.445 0.000*
A allele 253 (63.3) 84 (42) 0.419 1.68-3.66 0.000*
G allele 147(36.8) 116 (58)
NAT2 (G590A) GG 59 (29.5) 23 (23) Ref
AG 118 (59) 67 (67) 0.687 0.389-1.211 0.194
AA 23 (11.5) 10 (10) 0.897 0.370-2.173 0.809
G allele 236 (59) 113 (56.5) 0.793 0.64-1.27 0.0.588
A allele 164 (41) 87 (43.5)
NAT2 (G857A) GG 79 (39.5) 1 (1.0) Ref
GA 2 (1.0) 16 (16.0) 0.002 0.000-.019 0.000*
AA 119 (59.5) 83 (83.0) 0.018 0.002-.133 0.000*
G allele 160 (40) 16 (8) 0.13 4.43-0.13.7 0.000*
A allele 240 (60) 184 (92)
Key: Ref: reference. 
Table 4. Association between NAT 2 C481T, A803G, G590A and NAT2 G857Agenotype and Risk of CML
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29.0%, respectively (OR =0.044, 95% CI:0.020-0.095, 
p = 0. 000).
Frequency of the homozygous mutant 803GG and 
heterozygous 803AG was higher in the control than CML 
patients. Incidence of the homozygous mutant 803GG was 
found in 26% of the control as opposed to 10% of CML 
patients, (OR = 0.201, 95% CI:0.091-0.445, p = 0. 0.000), 
and presence of the heterozygous 803AG was 64% in the 
control and just 15.5% of CML cases (OR = 0.44, 95% 
CI: 0.020-095, p = 0. 000).
The mutant allele G was also significantly higher in 
control subjects when compared with cases at 58% and 
36%, respectively.
From NAT2 G590A samples, 590GG and 590AA 
genotype distribution was higher among CML patients 
(29.5%) and (11.5%) respectively, compared to control 
group (23.0%) and (10.0%). With OR = 0.897, 95% CI: 
0.370-2.137 and p = 0. 809 however, this difference was 
not considered significant. 
NAT2 590AG was higher in the healthy control (67%) 
than CML patients (59%), but again, with OR = 0.687, 
95% CI:0.389-1.211 and p = 0.194, this difference was 
not significant. Accordingly, presence of the G allele was 
higher in CML patients (59.0%) compared to the control 
(56.5%), but again of no significant difference (p = 0. 
558). NAT2 857GG was also higher in patients (39.5%) 
compared to the control (1.0%).
Figure 1. Detection of NAT2 Polymorphisms-C 481T on 
4% Agarose Gel. DNA product digested with restriction 
enzyme KpnI for C481T,. Lane 1: heterozygous CT 
(547,433 and 114 pb), lane 2, 3,4 and 5( un cut product 
547bp) homozygous mutant TT. Lane 6: : Molecular 
weight marker 100 bp. 
Figure 2. Detection of NAT2- Polymorphisms on 4% 
Agarose Gel. DNA product digested with restriction 
enzyme Taq1 for G590A, Lane 1: Molecular weight marker 
50 bp. Lane 2: hetrozygous GA (392,22,170&155bp). 
Lane 3: wild type GG(222,170&155bp). Lane 4: 
homozygoyous mutant AA (392&155bp). 
NAT2C481T and NAT2GA803G Case Odd ratio 95%CI P-value
Control N (%) Patient N (%)
Comb1 CC / AA 1 (1%) 4 (2%) Ref
CC / GG 1 (1%) 1 (0.5%) 0.25 (0.01- 8.56) 0.442
CT/ AA 3 (3%) 22 (11%) 1.83 (0.15  -  22.36) 0.635
CT / AG 11 (11%) 1 (0.5%) 0.023 (0.001 -.456) 0.013*
CT / GG 1 (1%) 15 (7.5%) 3.75 (0.190 - 74.06) 0.385
TT / AA 7 (7%) 84 (42%) 3 (0.294 -30.62) 0.354
TT/ AG 52 (52%) 31 (15.5%) 0.15 (0.016 -1.39) 0.095
TT / GG 24 (24%) 42 (21%) 0.44 (0.046 -4.14) 0.471
NAT2G590A and NAT2A803G Control N (%) Patient N (%) Odd ratio 95%CI P-value
Comb2 GG / AA 3 (3%) 32 (16%) Ref
GG / AG 17 (17%) 1 (0.5%) 0.01 (0.001 - 0.057) 0.000*
GG / GG 3 (3%) 27 (13.5%) 0.84 (0.157 - 4.53) 0.843
AG / AA 7 (7%) 59 (29.5%) 0.79 (0.191 -3.27) 0.745
AG / AG 38 (38%) 31 (15.5%) 0.08 (0.021-0.27) 0.000*
AG / GG 21 (21%) 27 (13.5%) 0.12 (0.032 -.45) 0.002*
AA / AA 1 (1%) 19 (9.5%) 1.7 (0.173 -18.37) 0.628
AA/ AG 10 (10%) 4 (2%) 0.04 (0.007-0.19) 0.000*
GG/ AA 3 (3%) 32 (16%) 0.141 (0.001 -0.06) 0.073*
Key: (*), denote; *, significant p. value
Table 5. NAT2 Genotype Interaction Analysis in CML Patient and Control 
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Frequency of 857GA and 857AA in the NAT2G857A 
genotype was higher in the control at 16.0% and 
83.0% respectively, as opposed to 1.0% and 59.5% of 
CML patients. This difference was highly significant, 
(OR = 0.002, 95% CI:0. 000-0.19, p = 0. 0.000) and (OR 
= 0.018, 95% CI:0.002- 0.133, p = 0. 0.000) respectively. 
Mutant allele A presence was significantly higher 
in the control, it being found in 92% of healthy 
participants as opposed to 60% of CML cases, (p = 0. 
0.000). Furthermore, logistical analysis of carriers of the 
homozygous mutant heterozygous to 1208 and rs1799931, 
were both associated with CML protection - unlike those 
with the homozygous wild type allele, (OR = 0.89, 95% 
CI: 0.044 -0.181, p=0.000) and (OR = 0.015, 95% CI: 
0.002-0.0113, p=0.000), respectively, Please see results 
in Table 4.
Frequency of NAT2 genotype combinations among 
patients and the control is found in Table 5. Within the 
NAT2C481T and NAT2GA803G combination, CTAGwas 
the only genotype represented significantly more in 
patients (11%) compared to control (0.5%) with (OR = 
.023, 95% CI: (.001 -.456, p = .013). CTAG is therefore 
associated with protection from CML.
Additionally, five polymorphisms were considered 
highly significant in decreasing CML risk and these had 
a synergistic effect on each other. They were represented 
in the following combinations:
NAT2481CT/NAT2 803AG (OR = 0.023, 95% CI: 
0.001 -0.456, p = 0 .013)
NAT2 590GG/ NAT2803AG (OR = 0.006, 95% CI: 
0.001 -.057, p = 0 .000)
 NAT2 590AG/ NAT2 803AG (OR = 0.076, 95% CI: 
0.21 -0.274, p= 0.000)
 NAT2590AG/ NAT2803GG (OR = 0.121, 95% CI: 
0.032 -0.448, p = 0.000)
 NAT2 590AA/ NAT2803AG (OR = 0.038, 95% CI: 
0.007 -0.197, p = 0.000) 
NAT2 590GG/ NAT2803AA (OR = 0.006, 95% CI: 
0.001 -0.057, p = 0.000).
Discussion
The NAT2 acetylated genotype has a large influence 
on cancer predisposition (Jiang et al., 2019) and may 
induce susceptibility to tumors arising from industrial 
and environmental aryl amines (Mitchell, 2019). To date, 
a limited number of studies have been published in Sudan 
concerning inter-individual and inter-ethnic differences 
in NAT2 allele frequencies, (Ali et al., 2019; Al-Yahyaee 
et al., 2007) but this is the first investigation into its 
genetic variations (481 C→T, 590 G→A, 803 A→G and 
857G→A) and their association with CML susceptibility 
and progression (Kotila et al., 2019).
Our results revealed no statistical difference in the 
presence of the heterozygous 481CT and mutant 590AA 
genotypes between CML patients and the control. In 
patients, 481CT genotype presence was actually slightly 
higher in patients (18.5%) than the control (15.0%), (OR 
= 0.617, 95% CI: 0.064-5.981, p = 0.677). Conversely, 
a slightly higher 481 TT genotype frequency was found 
in the control (84.0%), as opposed to (79.5%) of patients 
group. Again however, this was not significant difference 
(OR = 0.473, 95% CI:0.052-4.302, p = 0.506). 
Moreover, NAT2 590GA and AA presence was of no 
significant difference between diagnosed CML patients 
and the control (OR = 0.687, 95% CI: 0.389-2.1.211, 
p = 0. 194) and (OR = 0.897, 95% CI: 0.370-2.173, P = 0. 
809). These results are partially in agreement with Silveira 
and coworkers regarding NAT2 variant polymorphism 
presence, in ALL patients and their control (Silveira et al., 
2012). The current study is also partially consistent with 
an earlier study conducted by Lemos and co-workers, who 
failed to find an association between these polymorphisms 
and other types of hematological malignancy(Lemos et al., 
1999). Research by Ouerhani et al., (2011) investigated 
the association between xenobiotic metabolizing gene 
polymorphisms and susceptibility to AML, CML, CLL, 
and ALL in the Tunisian population, and found that NAT2 
polymorphisms do not influence either predisposition or 
prognosis in CML patients. 
More specifically, studies amongst Han Chinese 
populations found no significant association between 
rs1799930 and AML susceptibility which partially 
concords with Dursun et al, who revealed that rs1799929, 
rs1799930, and rs1799931 polymorphisms of the NAT-2 
gene are not risk factors for the development of psoriasis 
(Dursun et al., 2018; Zou et al., 2017). 
In contrast with our findings, another study has 
demonstrated that AML risk increases in patients with 
rapid or intermediate NAT2 genotypes (Ouerhani et al., 
2011), and Gra et al showed that NAT2 genotypes 341T/T, 
481C/C, 590G/G are more frequent in children with acute 
leukemia than in the population control (Gra et al., 2008). 
The association of NAT2 polymorphisms with 
the predisposition of acute leukemia has produced 
controversial results (Zhu et al., 2019). Gra et al., (2008) 
found ALL and AML patients expressed a rapid acetylation 
phenotype, suggesting that the increased frequency 
of malignancy (acute leukemia) was due to enhanced 
activation of aryl amines as potential pro-carcinogens. 
It is already been shown that the rapid acetylation 
phenotype occurs more frequently in patients with colon 
and colorectal cancer (Kabir and Rehman, 2018).
Gong et al., (2001) in addition to a meta-analysis 
of prostate cancer, disagree with studies undertaken on 
solid tumors in adults which demonstrate that NAT2 slow 
acetylator individuals are at a greater risk of prostate and 
lung cancer (Koda et al., 2017; Liu et al., 2015).
Our data demonstrates the protective effect of 
NAT2A 803G and G857A against CML. 803AG in 
its heterozygous form offers approximately 2.3 fold 
protection and the heterozygous (GA) and mutant (AA) 
in the 857G→A genotype, both decreased risk also. 
Our study is in harmony with Zou et al., (2017) who 
revealed that the rs1799931 G>A NAT2 gene replaced 
glycine by glutamic acid in the 286th amino acid of the 
protein. The locus mutation alters enzyme activity and 
the further effects of drug metabolism in the activation 
of carcinogens, in raising or lowering cancer incidence.
A major meta-analysis has reported rs1799931 as 
a protective factor against cancer progression (Tian et 
al., 2014). However, Kamel et al., (2015) reported that 
Entesar M Tebien et al
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NAT2*5B (314T>C, 481C>T and 803A>G) & *5C 
(314T>C,803A>G) were associated with a decreased risk 
of ALL development, giving 1.8 and 2.4-fold protection, 
respectively.
This study agrees with our finding that the 803A>G 
polymorphism is associated with CML protection, to some 
extent. Furthermore, we found that risk also decreased as a 
result of the G590A gene polymorphism, in its significant 
relationship with A803G and C481T - when in interaction 
with A803G. CML patients with compound NAT2 590GG/ 
NAT2803AG, NAT2 590AG/ NAT2803AG, NAT2 590AG/ 
NAT2803GG, NAT2 590AA/ NAT2803AG and NAT2 
590GG/ NAT2803AA genotypes were found to have a 
decreased risk.
The present results reveal these combinations as 
having a protective effect against CML development. 
However, Gra et al., (2008) found that the combination 
of GST and NAT2 genotypes greatly increased the risk 
of acute leukemia in childhood. This risk frequency was 
higher than those with the GSTT1 null genotype, GSTM1 
null genotype, or NAT2 genotypes; 341T/T, 481C/C and 
590G/G.
A previous study undertaken by Zheng et al., (2017) 
also documented the significant risk of ALL with carriers 
of rs1799931 and rs1801280, and that carriers of the 
rs1799931-GA/AA and rs1801280-TC/CC genotypes had 
the highest risk of all. 
Our study has several limitations specifically that more 
SNPs within the NAT2 gene should have been studied and 
sample size should have been larger. In addition, the CML 
phases should receive greater focus.
In conclusion, there is evidence that both NAT2A 
803G and G857A polymorphisms were associated 
with protection from CML in the Sudanese population. 
Also, the gene-gene interaction between NAT2 590GG/ 
NAT2803AG, NAT2 590AG/ NAT2803AG, NAT2 590AG/ 
NAT2803GG, NAT2 590AA/ NAT2803AG and NAT2 
590GG/ NAT2803AA genotypes were associated with 
a decreased CML risk. However, there was no such 
association between C481T and G590A and CML.
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